Figure 1. Cumulative incidence curve showing 10-year standardized cumulative incidences and absolute risk differences for skin cancer. The graph plots the risk of skin cancer (%) over time since CLL diagnosis (years) for patients with CLL and controls.

Individuals with #ChronicLymphocyticLeukemia faced increased risk of skin cancer-specific metastasis and death compared with controls especially #BasalCellCarcinoma and #SquamousCellCarcinoma, though the absolute risk remained low.

ja.ma/47yZ8ev

On World Cancer Day, let’s honour those we’ve lost, support those living with cancer, and raise awareness for better prevention and treatment options.

#WorldCancerDay #UnitedByUnique #bloodcancer #ChronicLymphocyticLeukemia

Frailty Scale May Predict Treatment Cessation in Older Patients With CLL Among patients with CLL aged 65 years or older receiving zanubrutinib, discontinuation at 12 months was higher in those with CFS above 3.

The Clinical Frailty Scale was associated with early treatment discontinuation among older adults with chronic lymphocytic leukemia (#CLL) treated with #Zanubrutinib. Study in Hematological Oncology.

Read more: https://bit.ly/4aTranu

#RareDisease #ChronicLymphocyticLeukemia #Hematology #Oncology

Researchers reveal #ferroptosis as a targetable vulnerability in #ChronicLymphocyticLeukemia, showing that BTK inhibition increases iron uptake via TFRC, and combining #ibrutinib with #GPX4 or ACSL1 targeting enhances ferroptosis.

#OpenAccess in #STTT: doi.org/10.1038/s413...

Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL Most patients with CLL who discontinued BTK inhibitors and later received BCL2i achieved early responses but poor long-term outcomes.

Patients with chronic lymphocytic leukemia (#CLL) who discontinued covalent #BTKi and later required #BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap.

Read here: https://bit.ly/3YkhbQn

#RareDisease #ChronicLymphocyticLeukemia #MedSky

#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg
#HemeSky #OncSky

Sustained CLL Clearance With Ven-Obi Supports Durable Immune Recovery Fixed-duration venetoclax–obinutuzumab sustained chronic lymphocytic leukemia (CLL) cell depletion while permitting measured immune recovery.

Venetoclax–obinutuzumab (#VenObi) demonstrated durable disease control with partial but steady immune restoration through 48 months. @ash.hematology.org

Read more: https://bit.ly/482ZHOf

#RareDisease #ChronicLymphocyticLeukemia #CLL #Hematology

In patients with #ChronicLymphocyticLeukemia #CLL, the use of regular prophylactic IgG replacement therapy to help prevent #infection, a common occurrence with the disease, was not associated with a reduced risk of infection-related hospitalizations: https://ow.ly/6L3W50XlOHU
#HemeSky #MedSky

Unraveling the Relationship Between CLL and Advanced Age While advanced age appears to be a risk factor for CLL, the development of CLL also worsens age-related outcomes.

In the American Journal of Hematology, Dr Michael Hallek of the @unicologne.bsky.social wrote about the common features of #ChronicLymphocyticLeukemia (CLL), including some of the more notable epidemiological findings in recent years.

Read more: bit.ly/4o3xzjv

#MedSky #RareSky #CLL

How Childhood Fascination Led to CLL Expertise—and Continued Hope Jennifer R. Brown, MD, PhD, is SOHO's annual honoree for outstanding achievement.

👏 From childhood curiosity to career achievement

Jennifer R. Brown, MD, PhD, Director of the CLL Center at @danafarber.bsky.social has dedicated her life to understanding and advancing treatment for #ChronicLymphocyticLeukemia (CLL). @societyofhemonc.bsky.social

Read more: https://bit.ly/476wgcs

MRD-Guided Treatment Approach Leads to Deep Remissions in CLL | ASH Clinical News | American Society of Hematology

Recent research indicates that MRD-guided time-limited treatment with #zanubrutinib, #venetoclax, and #obinutuzumab resulted in deep remissions in patients with previously treated #ChronicLymphocyticLeukemia, with a best uMRD rate of 85%: ow.ly/e16h50WwZ66
#HemeSky

As someone who has CLL this is encouraging news. #leukemia #bloodcancer #cll #chroniclymphocyticleukemia

I have been a cancer survivor for 2,238 days. Thank you ohyouresotough for the art work for National Cancer Survivors Day. #leukemia #chroniclymphocyticleukemia

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic...

📢New article alert

New Research Article in JCER compares healthcare resource utilization and costs for first-line treatments for #CLL.

🔗Read here: becarispublishing.com/doi/10.57264...

#ChronicLymphocyticLeukemia #HealthcareCosts #RealWorldData #OpenAccess #JCER

AstraZeneca’s Calquence-venetoclax combo shows incredible results for CLL patients. A hopeful step forward in cancer care. #CancerBreakthrough #LeukemiaTreatmen #Cancer #BloodCancer #Leukemia #CancerTreatment #ChronicLymphocyticLeukemia #MedicalBreakthrough #ScienceNews #HealthUpdates

It's done, my cancer journey in 4K. If you know anyone with #ChronicLymphocyticLeukemia, please share.

youtu.be/nHnK5bKx90s?...

#CLL #Leukemia #BloodCancer #chatgpt #midjourney #runway #rubbrband #flux #elvenlabs #suno #capcut #cordycepsmilitaris #cordyceps #4k

Would love to be included!I'm working on the immune microenvironment in #chroniclymphocyticleukemia 👋